Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
37062658
DOI
10.1016/j.clgc.2023.03.006
PII: S1558-7673(23)00065-4
Knihovny.cz E-resources
- Keywords
- Immunocombo, Immunotherapy, NCT05287464, Obesity, Survival, Tumor Response, mRCC,
- MeSH
- Body Mass Index MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Carcinoma, Renal Cell * pathology MeSH
- Humans MeSH
- Kidney Neoplasms * pathology MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Protein Kinase Inhibitors MeSH
BACKGROUND: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. RESULTS: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). CONCLUSION: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology Centre Hospitalier de Jolimont Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology Maggiore della Carità University Hospital Novara Italy
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn Bonn Germany
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Division of Medical Oncology National Cancer Centre Singapore Singapore
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria
IRCCS Ospedale Policlinico San Martino Genoa Italy
Markey Cancer Center University of Kentucky Lexington KY
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology Department La Paz University Hospital Madrid Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Medical Oncology Unit Santa Chiara Hospital Trento Italy
Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy
Oncology 3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padova Italy
Oncology Candiolo Cancer Institute IRCCS FPO Torino Italy
Oncology Unit 2 University Hospital of Pisa Pisa Italy
Oncology Unit A R N A S Civico Palermo Italy
Oncology Unit Macerata Hospital Macerata Italy
Unità di Oncologia Medica Azienda Ospedaliero Universitaria di Cagliari Cagliari Italy
UOC di Oncologia Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli Naples Italy
UOC Oncologia Azienda Ospedaliera Ospedali Riuniti Marche Nord Italy
Urologic Oncology Champalimaud Clinical Center Lisbon Portugal
References provided by Crossref.org
ClinicalTrials.gov
NCT05287464
